Answers are grounded in this paper and cite their sources.
The findings suggest that plasma NfL can be used as a noninvasive biomarker associated with neurodegeneration in patients with AD and may be useful to monitor effects in trials of disease-modifying drugs.
No takes yet. Share an insight, caveat, or question.
Mattsson et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: